Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer
Mukai, Hirofumi, Saeki, Toshiaki, Shimada, Ken, Naito, Yoichi, Matsubara, Nobuaki, Nakanishi, Tadashi, Obaishi, Hiroshi, Namiki, Masayuki, Sasaki, YasutsunaVolume:
33
Langue:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-014-0161-y
Date:
February, 2015
Fichier:
PDF, 285 KB
english, 2015